
Oruka Therapeutics rose 251.5% from $28.23 to $99.24, ahead of the S&P 500's +11.2%. Its worst day was Jul 2 (−8.7%), and its low came Jan 8 at $26.40.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Oruka Therapeutics shares rose 13.1%, while the S&P 500 rose 0.9%.
+13.1% · S&P 500 +0.9%
Oruka Therapeutics closed at its lowest level of the year, 6.5% below where the year started.
−5.1% · S&P 500 0.0%
Story events cover the past 12 months · Times ET
EPS of $-0.45 beat the $-0.61 estimate on $0.00 revenue.
+25.0%, the year's best day · S&P 500 −0.6%
EPS of $-0.48 beat the $-0.53 estimate on $0.00 revenue.
+1.1% · S&P 500 +0.8%
Oruka Therapeutics shares rose 18.0%, while the S&P 500 fell 0.3%.
+18.0% · S&P 500 −0.3%
Oruka Therapeutics shares rose 11.6%, while the S&P 500 fell 1.0%.
+11.6% · S&P 500 −1.0%
EPS of $-0.55 missed the $-0.50 estimate on $0.00 revenue.
+6.4% · S&P 500 0.0%
Oruka Therapeutics closed at its highest level of the year, 300.6% above where the year started.
+0.4% · S&P 500 −0.7%
61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-AContinued favorable safety and tolerability profile consistent with the IL-23p19 classORKA-001 on track to advance into
+12.7% · S&P 500 +0.7%
EPS of $-0.63 beat the $-0.63 estimate on $0.00 revenue.
+4.7% · S&P 500 −0.4%
Where it ended: a close of $99.24 on Nov 16, 2026. Up next: Q4 2026 earnings on Mar 11, 2027 (EPS est. $-0.72).
Nothing in the past 12 months.
All ORKA dividend historyAs of the Nov 16, 2026 close
Replay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ORKA and SPY from Benzinga historical bars. Not investment advice.